Table 2.
Association between gene promoter methylation and clinicopathological features ER and p53 expression in breast cancer.
| BRCA1 | hMLH1 | ||||||
|---|---|---|---|---|---|---|---|
| M (%) | U (%) | P(b) | M (%) | U (%) | P(b) | ||
| N | 78 | 35 (44.8) | 43 (55.1) | 17 (21.7) | 57 (73) | ||
| Age | |||||||
| ≤45 | 30 | 19 (63.3) | 11 (36.7) | 6 (21.4) | 22 (78.6) | ||
| >45 | 48 | 16 (33.3) | 32 (66.7) | 11 (23.9) | 35 (76.1) | ||
| .01 | .8 | ||||||
| Tumor size | |||||||
| T ≤ 30 mm | 38 | 18 (47.4) | 20 (52.6) | 3 (8.1) | 34 (91.9) | ||
| T > 30 mm | 40 | 17 (42.5) | 23 (57.5) | 14 (37.8) | 23 (62.2) | ||
| .66 | .002 | ||||||
| (a)Metastasis | |||||||
| No | 37 | 18 (48.6) | 19 (51.4) | 1 (2.8) | 35 (97.2) | ||
| Yes | 14 | 8 (37.1) | 6 (42.9) | 4 (30.8) | 9 (69.2) | ||
| .58 | .004 | ||||||
| (a)DFS | |||||||
| <5 years | 22 | 7 (31.8) | 15 (68.2) | 3 (14.3) | 18 (87.5) | ||
| >5 years | 12 | 9 (75) | 3 (25) | 1 (8.3) | 11 (91.7) | ||
| .015 | .6 | ||||||
| (a)Response to radiotherapy | |||||||
| Radiosensitive | 37 | 18 (48.6) | 19 (51.4) | 1 (2.8) | 35 (97.2) | ||
| Radioresistant | 14 | 8 (57.1) | 6 (42.9) | 4 (30.8) | 9 (69.2) | ||
| .58 | .004 | ||||||
| ER | |||||||
| Positive | 19 | 9 (47.4) | 10 (52.6) | 7 (36.8) | 12 (63.2) | ||
| Moderate | 28 | 11 (39.3) | 17 (60.7) | 2 (7.7) | 24 (92.3) | ||
| Negative | 31 | 15 (48.4) | 16 (51.6) | 8 (27.6) | 21 (72.4) | ||
| .75 | .054 | ||||||
| (a)P53 | |||||||
| Positive | 16 | 9 (56.3) | 7 (43.8) | ||||
| Negative | 23 | 10 (43.5) | 13 (56.5) | 5 (68.8) | 11 (31.3) | ||
| 0 (0) | 21 (100) | ||||||
| .44 | .006 | ||||||
DFS: Disease Free Survival, ER: Estrogen Receptor.
(a)Data for DFS, response to radiotherapy, metastasis, and p53 status were not available for all specimens.
(b)Comparisons of DFS and P53 status was made by Fisher's exact test and all other comparisons were by the 2 test.